COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
NanoViricides, Inc. announces closing of $2M direct offering. Exclusive placement agent D. Boral Capital LLC. SEC registration effective. NV-387, a revolutionary antiviral drug granted Orphan Drug Designation -
-
-
COMMUNIQUÉ DE PRESSE
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
NanoViricides, Inc. highlights the urgent need for a broad-spectrum antiviral drug like NV-387 amid an Ebolavirus outbreak in DR Congo and Uganda. NV-387 holds promise as it targets sulfated proteoglycans crucial for viral attachment to cells -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
NanoViricides, Inc. announces a registered direct offering of common shares and warrants to a fundamental institutional investor for gross proceeds of approximately US$2 million. D. Boral Capital LLC acts as the exclusive placement agent for the Offering
